Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals

Nabarro, 2015, Combination therapy for carbapenem-resistant Enterobacteriaceae: increasing evidence, unanswered questions, potential solutions, Eur J Clin Microbiol Infect Dis, 34, 2307, 10.1007/s10096-015-2486-7 Tzouvelekis, 2014, Treating infections caused by carbapenemase-producing Enterobacteriaceae, Clin Microbiol Infect, 20, 862, 10.1111/1469-0691.12697 Lagerbäck, 2016, Evaluation of antibacterial activities of colistin, rifampicin and meropenem combinations against NDM-1-producing Klebsiella pneumoniae in 24 h in vitro time–kill experiments, J Antimicrob Chemother, 71, 2321, 10.1093/jac/dkw213 Song, 2007, In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii, J Antimicrob Chemother, 60, 317, 10.1093/jac/dkm136 Tascini, 2013, Synergistic activity of colistin plus rifampin against colistin-resistant KPC-producing Klebsiella pneumoniae, Antimicrob Agents Chemother, 57, 3990, 10.1128/AAC.00179-13 Deris, 2012, The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model, Antimicrob Agents Chemother, 56, 5103, 10.1128/AAC.01064-12 Zusman, 2013, Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems, Antimicrob Agents Chemother, 57, 5104, 10.1128/AAC.01230-13 Pournaras, 2011, Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay, Int J Antimicrob Agents, 27, 244, 10.1016/j.ijantimicag.2010.10.031 Yadav, 2015, Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumannii, Antimicrob Agents Chemother, 59, 2286, 10.1128/AAC.04379-14 Bulik, 2011, Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae, Antimicrob Agents Chemother, 55, 3002, 10.1128/AAC.01420-10 Oliva, 2016, Bactericidal and synergistic activity of double-carbapenem regimen for infections caused by carbapenemase-producing Klebsiella pneumoniae, Clin Microb Infect, 22, 147, 10.1016/j.cmi.2015.09.014 Petrosillo, 2014, Clinical experience of colistin–glycopeptide combination in critically ill patients infected with Gram-negative bacteria, Antimicrob Agents Chemother, 58, 851, 10.1128/AAC.00871-13 Falagas, 2010, Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients, Int J Antimicrob Agents, 35, 10.1016/j.ijantimicag.2009.10.005 Zarkotou, 2011, Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment, Clin Microbiol Infect, 17, 1798, 10.1111/j.1469-0691.2011.03514.x Tumbarello, 2012, Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy, Clin Infect Dis, 55, 943, 10.1093/cid/cis588 Gutiérrez-Gutiérrez, 2017, Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study, Lancet Infect Dis, 17, 726, 10.1016/S1473-3099(17)30228-1 Paul, 2014, Combination therapy for carbapenem-resistant Gram-negative bacteria, J Antimicrob Chemother, 69, 2305, 10.1093/jac/dku168 Zusman, 2017, Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis, J Antimicrob Chemother, 72, 29, 10.1093/jac/dkw377 SurveyMonkey. Free online survey & questionnaire tool [Internet]. San Mateo, California, USA: SurveyMonkey Inc.; 1999–2017 [cited 2017 Aug 12]. Available at: http://www.surveymonkey.com. Magiorakos, 2012, Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance, Clin Microbiol Infect, 18, 268, 10.1111/j.1469-0691.2011.03570.x Durante-Mangoni, 2013, Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial, Clin Infect Dis, 57, 349, 10.1093/cid/cit253 Aydemir, 2013, Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia, Epidemiol Infect, 141, 1214, 10.1017/S095026881200194X Sirijatuphat, 2014, Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections, Antimicrob Agents Chemother, 58, 5598, 10.1128/AAC.02435-13 Petrosillo, 2008, Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies, Clin Microbiol Infect, 14, 816, 10.1111/j.1469-0691.2008.02061.x Paul, 2014, β lactam antibiotic monotherapy versus β lactam-aminoglycoside antibiotic combination therapy for sepsis, Cochrane Database Syst Rev [Internet], 10.1002/14651858.CD003344.pub3 Paul, 2013, β-lactam versus β-lactam-aminoglycoside combination therapy in cancer patients with neutropenia, Cochrane Database Sys Rev [Internet], 10.1002/14651858.CD003038.pub2 Marcus, 2011, Clinical implications of β-lactam-aminoglycoside synergism: systematic review of randomised trials, Int J Antimicrob Agents, 37, 491, 10.1016/j.ijantimicag.2010.11.029 Bliziotis, 2005, Effect of aminoglycoside and β-lactam combination therapy versus β-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials, Clin Infect Dis, 41, 149, 10.1086/430912 Vardakas, 2016, Clostridium difficile infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis, Int J Antimicrob Agents, 48, 1, 10.1016/j.ijantimicag.2016.03.008 Schwaber, 2008, Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality, Antimicrob Agents Chemother, 52, 1028, 10.1128/AAC.01020-07